Telix Pharmaceuticals Ltd
TLXNasdaqHealthcare · Pharmaceutical Preparations · C3 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
FDA-approved drugs
openFDA · most recent- ILLUCCIXDec 17, 2021
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2024-12Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
- Phase 3Recruitingreadout ~2025-12-3068Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
- Phase 1Recruitingreadout ~2026-0389Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
- Phase 1Recruitingreadout ~2026-06131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
- Phase 3Recruitingreadout ~2026-06PSMA PET Combined With MRI for the Detection of PCa
- Phase 3Recruitingreadout ~2026-06-3089Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
- Phase 1Recruitingreadout ~2027-04-26Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
- Phase 3Recruitingreadout ~2027-07Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Behrenbruch ChristianPassive (13G)Feb 14, 2025
- Kluge AndreasPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 217,298 | 1.9 | -19.6% |
| Apr 30, 2026 | 270,088 | 1.5 | -30.9% |
| Apr 15, 2026 | 390,717 | 1.6 | +27.7% |
| Mar 31, 2026 | 306,000 | 1.2 | +69.2% |
| Mar 13, 2026 | 180,832 | 1.0 | -51.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Recent SEC filings
All filings ↗- 6-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSMay 21, 2026
- 3FORM 3May 18, 2026
- 3FORM 3May 18, 2026
- 3FORM 3May 18, 2026
- 4FORM 4May 6, 2026
- 6-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 23, 2026
- 6-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 21, 2026
- 6-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 20, 2026
- 6-KApr 14, 2026
- 6-KApr 14, 2026
- 6-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 13, 2026
- 6-KApr 10, 2026
- 6-KApr 9, 2026
- 6-KApr 7, 2026
- 6-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 2, 2026